CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026)
CV Sciences (CVSI) reported Income from Continuing Operations of 643000.0 for Q1 2026, down 489.91% on a YoY basis from 164910.59 in Q1 2025, and down 499.38% sequentially from 161000.0 in Q4 2025.
CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Income from Continuing Operations data on file, last reported at 643000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 489.91% year-over-year to 643000.0; the trailing twelve-month figure through Mar 2026 stood at 1125000.0 (up 30.3% YoY), and the FY2025 full-year result was 591000.0, up 72.29% from the prior year.
- Income from Continuing Operations eased to 643000.0 in Q1 2026, from 161000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5706000.0 in Q1 2023 to a low of 2653000.0 in Q2 2022.
- A 5-year average of 394294.12 and a median of 584000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations sank 2477.5% in 2022 and jumped 369.79% in 2023, its largest moves.
- Tracing CVSI's Income from Continuing Operations over 5 years: stood at 625000.0 in 2022, then sank by 41.28% to 883000.0 in 2023, then jumped by 47.34% to 465000.0 in 2024, then surged by 134.62% to 161000.0 in 2025, then sank by 499.38% to 643000.0 in 2026.
- Business Quant data shows CVSI's Income from Continuing Operations at 643000.0 in Q1 2026, 161000.0 in Q4 2025, and 382000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | -643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -465,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -883,000.00 |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -625,000.00 |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.12 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -3.53 Mn |